Cargando…

Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest

The German Psoriasis Registry PsoBest was conducted in 2008 in order to investigate the long-term outcomes and safety of systemic treatments for moderate-to-severe psoriasis. Safety analysis of antipsoriatic drugs with special focus on serious adverse events (SAE) for infections, malignancies and ma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Reich, K., Mrowietz, U., Radtke, M. A., Thaci, D., Rustenbach, S. J., Spehr, C., Augustin, M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2015
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4643107/ https://www.ncbi.nlm.nih.gov/pubmed/26358263 http://dx.doi.org/10.1007/s00403-015-1593-8

Ejemplares similares

CoronaBest und PsoBest Bioscience: Neue Ausbaustufen beim Deutschen Psoriasis-Register
por: Gehoff, Mario
Publicado: (2020)

The German National Program on Psoriasis Health Care 2005–2015: results and experiences
por: Augustin, M., et al.
Publicado: (2016)

Nail psoriasis as a severity indicator: results from the PsoReal study
por: Radtke, Marc A, et al.
Publicado: (2010)

Quality-of-Life Outcomes, Effectiveness and Tolerability of Apremilast in Patients with Plaque Psoriasis and Routine German Dermatology Care: Results from LAPIS-PSO
por: Reich, Kristian, et al.
Publicado: (2021)

Secukinumab efficacy in reducing the severity and the psychosocial impact of moderate‐to‐severe psoriasis as assessed by the Simplified Psoriasis Index: results from the IPSI‐PSO study
por: Richard, M.‐A., et al.
Publicado: (2020)

A 24‐week multicentre, randomized, open‐label, parallel‐group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate‐to‐severe plaque psoriasis naive to systemic treatment
por: Reich, K., et al.
Publicado: (2019)

German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version)
por: Nast, A., et al.
Publicado: (2007)

Real-world effectiveness of anti-interleukin-23 antibodies in chronic plaque-type psoriasis of patients from the Austrian Psoriasis Registry (PsoRA)
por: Graier, T., et al.
Publicado: (2022)

Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study—IL PSO (Italian landscape psoriasis)
por: Gargiulo, Luigi, et al.
Publicado: (2023)

Implementation of the PsoWell™ Model for the Management of People with Complex Psoriasis
por: HEWITT, Rachael M., et al.
Publicado: (2021)

Sex-related impairment and patient needs/benefits in anogenital psoriasis: Difficult-to-communicate topics and their impact on patient-centred care
por: da Silva, Neuza, et al.
Publicado: (2020)

Low Pneumococcal Vaccination among Patients with Psoriasis in Germany: Results from Vac-Pso
por: Wellmann, Phoebe, et al.
Publicado: (2022)

Management der Psoriasis
por: Mrowietz, Ulrich
Publicado: (2021)

Drug survival of biologic therapy in a large, disease‐based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)
por: Menter, A., et al.
Publicado: (2016)

PsoBarrier EU study: a Multicentre, Cross-sectional Survey Investigating the Quality of Psoriasis Care in Four European Countries
por: LANGENBRUCH, Anna, et al.
Publicado: (2023)

Long-Term Safety and Effectiveness of Adalimumab for Moderate to Severe Psoriasis: Results from 7-Year Interim Analysis of the ESPRIT Registry
por: Menter, Alan, et al.
Publicado: (2017)

Comparative effectiveness of biologics for patients with moderate-to-severe psoriasis and special area involvement: week 12 results from the observational Psoriasis Study of Health Outcomes (PSoHO)
por: Piaserico, Stefano, et al.
Publicado: (2023)

Safety of Brodalumab in Plaque Psoriasis: Integrated Pooled Data from Five Clinical Trials
por: REICH, Kristian, et al.
Publicado: (2022)

Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate‐to‐severe psoriasis through 5 years of treatment (SCULPTURE Extension Study)
por: Bissonnette, R., et al.
Publicado: (2018)

Updates in psoriasis diagnosis and treatment status in China: results from the National Psoriasis Center Registry
por: Yang, Zhihui, et al.
Publicado: (2023)

Association Between Patient- and Physician-Reported Outcomes in Patients with Moderate-To-Severe Plaque Psoriasis Treated with Biologics in Real Life (PSO-BIO-REAL)
por: Lacour, Jean-Philippe, et al.
Publicado: (2020)

Characteristics of Patients with Psoriasis Treated with Apremilast in the Corrona Psoriasis Registry
por: Gottlieb, Alice B., et al.
Publicado: (2021)

Network meta‐analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values ≤1, 2, 3 or 5 derived from a statistical conversion method
por: Mrowietz, U., et al.
Publicado: (2021)

Switching from a fumaric acid ester mixture to dimethylfumarate monotherapy in psoriasis
por: Warren, R.B., et al.
Publicado: (2019)

Real‐life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52‐week multicentre retrospective study—IL PSO (Italian landscape psoriasis)
por: Narcisi, Alessandra, et al.
Publicado: (2022)

Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE Study
por: Paul, Carle, et al.
Publicado: (2017)

Psoriasis pathogenesis – Pso p27 constitutes a compact structure forming large aggregates
por: Lysvand, Hilde, et al.
Publicado: (2015)

Brodalumab for the treatment of plaque psoriasis in a real-life setting: a 3 years multicenter retrospective study—IL PSO (Italian landscape psoriasis)
por: Gargiulo, Luigi, et al.
Publicado: (2023)

Effectiveness of Biologics, Patient-Reported Outcomes, and Clinical Photography in a Subset of Patients with Moderate-to-Severe Psoriasis: Week 12 Results from the Psoriasis Study of Health Outcomes (PSoHO)
por: Travaglini, Massimo, et al.
Publicado: (2023)

Treatment Options and Goals for Patients with Generalized Pustular Psoriasis
por: Krueger, James, et al.
Publicado: (2022)

A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate‐to‐severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO‐BIO‐REAL)
por: Seneschal, J., et al.
Publicado: (2020)

Spotlight on Topical Long-Term Management of Plaque Psoriasis
por: Carrascosa, Jose Manuel, et al.
Publicado: (2020)

Practical recommendations for systemic treatment in psoriasis according to age, pregnancy, metabolic syndrome, mental health, psoriasis subtype and treatment history (BETA‐PSO: Belgian Evidence‐based Treatment Advice in Psoriasis; part 1)
por: Lambert, J.L.W., et al.
Publicado: (2020)

Validation of a new tool to assess health-related quality of life in psoriasis: the PSO-LIFE questionnaire
por: Dauden, Esteban, et al.
Publicado: (2012)

Exploring the Association Between History of Psoriasis (PSO) and Disease Activity in Patients with Psoriatic Arthritis (PsA)
por: Li, Shan-Shan, et al.
Publicado: (2022)

Symptom Experience and Content Validity of the Psoriasis Symptom Scale (PSS) in Patients with Generalized Pustular Psoriasis (GPP)
por: Burden, A. David, et al.
Publicado: (2022)

Pregnancy Outcomes in Women With Moderate-to-Severe Psoriasis From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)
por: Kimball, Alexa B., et al.
Publicado: (2021)

Quality of life and patient‐perceived symptoms in patients with psoriasis undergoing proactive or reactive management with the fixed‐dose combination Cal/BD foam: A post‐hoc analysis of PSO‐LONG
por: Jalili, A., et al.
Publicado: (2021)

Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S)
por: Wasel, Norman, et al.
Publicado: (2020)

Mediators of Pruritus in Psoriasis
por: Reich, Adam, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_ragqasbs28vk203suvo4mtsp2i